2025REBOOTbeta-blockerIn 8,505 patients after myocardial infarction with LVEF >40%, beta-blocker therapy did not reduce death, reinfarction, or HF hospitalisation compared with no beta-blocker.
2024DanGer ShockCardiogenic shockIn 360 patients with STEMI-related cardiogenic shock, a microaxial flow pump (Impella CP) reduced 180-day all-cause mortality compared with standard care.
2024REDUCE-AMIbeta-blockerIn 5,020 patients after acute MI with preserved LVEF (≥50%), beta-blocker therapy did not reduce all-cause death or new MI compared with no beta-blocker.
2023ORBITA-2RevascularisationIn 301 patients with stable angina on no antianginal medication, PCI improved the angina symptom score compared with a placebo procedure.
2022FAME 3FFR-guided PCIIn 1,500 patients with 3-vessel coronary disease, FFR-guided PCI did not prove non-inferior for 1-year death, MI, stroke, or repeat revascularisation compared with CABG.
2022REVIVED-BCIS2PCI vs OMTIn 700 patients with ischaemic LV dysfunction (LVEF ≤35%) and viable myocardium, PCI plus optimal medical therapy did not reduce all-cause death or HF hospitalisation compared with optimal medical therapy alone.
2020ISCHEMIARevascularisationIn 5,179 patients with stable CAD and moderate-to-severe ischaemia, an initial invasive strategy did not reduce CV death, MI, hospitalisation for unstable angina, HF or resuscitated arrest compared with an initial conservative strategy.
2019ISAR-REACT 5AntiplateletsIn 4,018 patients with acute coronary syndromes managed invasively, prasugrel reduced death, MI or stroke at one year compared with ticagrelor.
2019COMPLETERevascularisationIn 4,041 STEMI patients with multivessel disease, staged complete revascularisation reduced CV death or MI compared with culprit-lesion-only PCI.
2018ORBITARevascularisationIn 200 patients with stable single-vessel angina, PCI did not improve exercise time at 6 weeks compared with a sham procedure.
2018SCOT-HEARTCT coronary angiographyIn 4,146 patients with stable chest pain, adding CT coronary angiography reduced 5-year coronary death or non-fatal MI compared with standard care alone.
2016EXCELleft main PCIIn 1,905 patients with left main disease of low-to-intermediate complexity, PCI with everolimus-eluting stents was non-inferior for 3-year death, stroke, or MI compared with CABG.
2016NOBLEleft main PCIIn 1,201 patients with unprotected left main coronary disease, PCI with drug-eluting stents increased 5-year death, MI, repeat revascularisation, or stroke compared with CABG.
2012FREEDOMPCI vs CABGIn 1,900 patients with diabetes and multivessel coronary disease, PCI with drug-eluting stents increased death, nonfatal MI, or nonfatal stroke compared with CABG.
2012FAME 2FFR-guided PCIIn 888 patients with stable coronary disease and a functionally significant (FFR ≤0.80) stenosis, FFR-guided PCI plus medical therapy reduced death, MI, or urgent revascularisation compared with medical therapy alone.
2009PLATOAntiplateletsIn 18,624 patients hospitalised with ACS, ticagrelor reduced CV death, MI or stroke compared with clopidogrel, with similar major bleeding.
2009FAMERevascularisationIn 1,005 patients with multivessel CAD, FFR-guided PCI reduced MACE at one year versus angiography-guided PCI.
2009SYNTAXPCI vs CABGIn 1,800 patients with 3-vessel or left main coronary disease, PCI with paclitaxel-eluting stents increased 12-month death, stroke, MI, or repeat revascularisation compared with CABG.
2007TRITON-TIMI 38AntiplateletsIn 13,608 ACS patients undergoing planned PCI, prasugrel reduced ischaemic events but increased major bleeding relative to clopidogrel.
2007COURAGERevascularisationIn 2,287 patients with stable coronary artery disease, PCI added to optimal medical therapy did not reduce death or non-fatal MI compared with optimal medical therapy alone.
2005COMMITclopidogrelIn 45,852 patients with acute myocardial infarction, clopidogrel added to aspirin reduced death, reinfarction, or stroke compared with placebo.
2001CUREAntiplateletsIn 12,562 patients with NSTE-ACS, clopidogrel plus aspirin reduced the composite of CV death, MI or stroke versus aspirin alone.
2001TACTICS-TIMI 18early invasive strategyIn 2,220 patients with NSTE-ACS treated with tirofiban, an early invasive strategy reduced 6-month death, MI, or rehospitalisation for ACS compared with a conservative strategy.
2000HOPEACE inhibitorIn 9,297 high-risk patients with vascular disease or diabetes and preserved LV function, ramipril reduced MI, stroke, or cardiovascular death compared with placebo.
1988ISIS-2ReperfusionIn 17,187 patients with suspected acute myocardial infarction, aspirin plus intravenous streptokinase reduced 5-week vascular mortality compared with placebo.